CMPS Compass Pathways Plc
Company Analysis
Latest News
🟢 Compass Pathways is trading 6.75% up in pre-market — catalyst remains unclear
Compass Pathways is trading 6.75% up at $14.13 after no clear September 2, 2026 company-specific catalyst was identified. - The latest surfaced disclosures...
🔴 Compass Pathways falls 5.1% — Biotech Sector Declines Amid Fed Rate Hike Fears
With Biotech (XBI) down 2.3%, this looks like a sector-led move rather than a company-specific surprise. The biotech sector, as measured by the XBI ETF, fell...
Compass Pathways downgraded to strong sell, following $1.88 per share loss
Wall Street Zen downgraded Compass Pathways Plc to a strong sell rating on August 24, 2026. The downgrade follows a quarterly earnings report showing a loss...
🟢 Compass Pathways is trading 7% up today, with no clear catalyst identified
Compass Pathways is trading $14.22, up 6.71%, on August 24, 2026, with no clear company-specific catalyst identified. - Recent updates, including August 5...
🔴 Compass Pathways is trading 5% down today after no clear company-specific announcement emerged
Compass Pathways is trading 5.12% down now at $13.49 after no clear company-specific announcement emerged on August 13, 2026. - The August 12 Canaccord...
🟢 Compass Pathways is trading 5% up today amid supportive markets and conference focus
Compass Pathways is trading 5.08% up at $14.06, supported by broader market strength and investor attention ahead of management’s scheduled fireside chat. -...
Compass Pathways Posts a $254 Million Loss That Barely Matters — But Can the Stock Hold Its Gains Until the FDA Decides?
Shares of Compass Pathways surged 11.4% to $13.14 on August 7, two days after the psychedelic-therapy developer reported second-quarter results that looked...
🟢 Compass Pathways is trading 11.4% up today as COMP360 NDA remains on track for Q4 2026
Compass Pathways is trading 11.4% up now at $13.14 after its Q2 update highlighted a steady clinical timeline and strong cash reserves. • The company...
🟢 Compass Pathways is trading 6.3% up today after Q2 results and reaffirmed COMP360 launch timeline
Compass Pathways is trading at $12.54 (up 6.3%) after reporting Q2 2026 results that confirmed a strong cash position and reaffirmed the regulatory timeline...
Compass Pathways reports wider second quarter loss of $1.88/share on non-cash charge, ends period with $433M in cash.
Compass Pathways reported a second quarter net loss of $1.88 per share, significantly wider than the prior year, primarily due to a large non-cash fair value...
🟢 Compass Pathways is trading 5.16% up today ahead of Q2 earnings and a broader biotech rally
Compass Pathways is trading at $11.83 (5.16%) up today as investors position for the company's Q2 earnings report on August 5, 2026, amid a broader surge in...
Compass Pathways Plc Q2 2026 Earnings Preview: What Analysts Expect on August 05, 2026
Consensus estimates for Compass Pathways indicate a Q2 2026 loss of $0.46 per share on zero revenue, with the current stock price of $11.35 trading...
🟢 Compass Pathways is trading 6.65% up today despite no clear company-specific catalyst
Compass Pathways is trading at $12.11 (+6.65%) in pre-market following a notable gap up, though the specific driver for the move remains unidentified. • No...
Compass Pathways Plc Q2 2026 Earnings Preview: What Analysts Expect on July 30, 2026
Compass Pathways is expected to post a Q2 loss of $0.46 per share on zero revenue, with its current $8.42 share price trading significantly lower than the...
🔴 Compass Pathways falls 5.3% — Biotech Stocks Decline on Broad Market Weakness
With Biotech (XBI) down 2.2%, this looks like a sector-led move rather than a company-specific surprise. The biotechnology sector, as measured by the XBI ETF,...
🔴 Compass Pathways is trading 5.65% down today amid broader biotech and Nasdaq weakness
Compass Pathways is trading 5.65% down at $11.05 amid a broader market rotation away from high-beta biotech names and general Nasdaq weakness. • The move...
🔴 Compass Pathways is trading 5% down today as investors reduce risk ahead of key data
Compass Pathways is trading 5% down at $11.73 amid pressure on high-beta biotech stocks and risk reduction ahead of key clinical milestones. • No...
🔴 Compass Pathways is trading 5.2% down today as profit-taking follows a sharp Phase 3 trial rally
Compass Pathways is trading 5.2% down today at $12.62 as investors lock in profits following a significant rally driven by Phase 3 trial results. • The stock...
🟢 Compass Pathways is trading 7.8% up today on continued momentum from Phase 3 depression trial data
Compass Pathways is trading about 7.8% up today at $14.35, extending gains following positive six-month Phase 3 COMP006 trial data for its treatment-resistant...
🟢 Compass Pathways rises 7.6% on positive six-month Phase 3 trial data, reinforcing confidence in COMP360's path to FDA approval
• Compass Pathways' COMP360 psilocybin therapy demonstrated rapid and durable efficacy in new six-month data from a second Phase 3 trial for...